Steinberg, P, McNutt, B E, Marshall, P et al. · The Journal of allergy and clinical immunology · 1996 · DOI
Researchers tested whether terfenadine, an antihistamine medication, could help reduce ME/CFS symptoms in 28 patients over two months. Despite finding that most ME/CFS patients had signs of allergies, the medication showed no benefit for fatigue, functioning, or overall well-being compared to placebo. This study suggests antihistamines are unlikely to be an effective treatment for ME/CFS.
This rigorous placebo-controlled trial definitively tested a plausible immunological hypothesis—that antihistamines might benefit ME/CFS patients with documented allergic responses. The negative result helps prevent ineffective treatments from being recommended and redirects research toward more promising therapeutic approaches.
This study does not prove that immune dysregulation plays no role in ME/CFS, only that antihistamine treatment is not effective despite immune abnormalities being present. It also does not rule out potential benefits in subsets of patients with specific allergic conditions, nor does it address whether other immunological interventions might be helpful.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →